AU781855B2 - Rhodamine derivatives for photodynamic diagnosis and treatment - Google Patents

Rhodamine derivatives for photodynamic diagnosis and treatment Download PDF

Info

Publication number
AU781855B2
AU781855B2 AU76357/00A AU7635700A AU781855B2 AU 781855 B2 AU781855 B2 AU 781855B2 AU 76357/00 A AU76357/00 A AU 76357/00A AU 7635700 A AU7635700 A AU 7635700A AU 781855 B2 AU781855 B2 AU 781855B2
Authority
AU
Australia
Prior art keywords
cells
pharmaceutical composition
patient
photoactivable
graft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU76357/00A
Other languages
English (en)
Other versions
AU7635700A (en
Inventor
Martin Guimond
Nestor A. Molfino
Denis-Claude Roy
Luc Villeneuve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montreal
Hopital Maisonneuve Rosemont
Original Assignee
Universite de Montreal
Hopital Maisonneuve Rosemont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Montreal, Hopital Maisonneuve Rosemont filed Critical Universite de Montreal
Publication of AU7635700A publication Critical patent/AU7635700A/en
Application granted granted Critical
Publication of AU781855B2 publication Critical patent/AU781855B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Agression treatment or altering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU76357/00A 1999-10-05 2000-10-03 Rhodamine derivatives for photodynamic diagnosis and treatment Expired AU781855B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15779099P 1999-10-05 1999-10-05
US60/157790 1999-10-05
PCT/CA2000/001142 WO2001024824A1 (en) 1999-10-05 2000-10-03 Rhodamine derivatives for photodynamic diagnosis and treatment

Publications (2)

Publication Number Publication Date
AU7635700A AU7635700A (en) 2001-05-10
AU781855B2 true AU781855B2 (en) 2005-06-16

Family

ID=22565296

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76357/00A Expired AU781855B2 (en) 1999-10-05 2000-10-03 Rhodamine derivatives for photodynamic diagnosis and treatment

Country Status (12)

Country Link
EP (1) EP1267931B1 (de)
JP (3) JP4859319B2 (de)
KR (1) KR100697400B1 (de)
AT (1) ATE285793T1 (de)
AU (1) AU781855B2 (de)
BR (1) BR0014135A (de)
CA (2) CA2699662A1 (de)
DE (1) DE60017201T2 (de)
ES (1) ES2234668T3 (de)
MX (1) MXPA02003522A (de)
PT (1) PT1267931E (de)
WO (1) WO2001024824A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409564B2 (en) 1999-10-05 2013-04-02 Universite De Montreal Rhodamine derivatives for photodynamic diagnosis and treatment
CA2342675A1 (en) 2001-04-02 2002-10-02 Abdelkrim Habi Halogenated rhodamine derivatives and applications thereof
WO2002079183A1 (en) * 2001-04-02 2002-10-10 Theratechnologies Inc. Halogenated rhodamine derivatives and applications thereof
EP1469733A4 (de) * 2001-11-29 2008-07-23 Therakos Inc Verfahren zur vorbehandlung eines patienten mit extrakorporaler photopherese und/oder apoptotischen zellen
JP4901479B2 (ja) * 2003-12-05 2012-03-21 ユニヴェルシテ ドゥ モントリオール 免疫疾患、感染症および癌の阻止、保護、予防または治療のための免疫学的化合物
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
EP3058957A1 (de) 2015-02-19 2016-08-24 Kiadis Pharma Intellectual Property BV Verbessertes fotodynamisches Verfahren und daraus hergestelltes Produkt
RU2637279C2 (ru) * 2015-12-25 2017-12-01 Сергей Петрович Кречетов Способ фотодинамической терапии
TWI715927B (zh) * 2019-02-01 2021-01-11 國立清華大學 組合物用於製備治療癌細胞的藥物的用途
EP3730627A1 (de) 2019-04-25 2020-10-28 Kiadis Pharma Intellectual Property BV Verfahren zur überprüfung der spenderidentität
EP3769770A1 (de) 2019-07-23 2021-01-27 Kiadis Pharma Intellectual Property BV Verfahren zur hemmung oder prävention von infektionen bei einem transplantatempfänger
CN115960090B (zh) * 2022-12-30 2024-03-29 中山大学 一种罗丹明b修饰吡啶配体的制备方法及其光催化抗菌应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321919A (en) * 1979-12-11 1982-03-30 Leukocyte Research, Inc. Method and system for externally treating human blood
WO1993000005A1 (en) * 1991-06-21 1993-01-07 Baxter International Inc. Method for inactivating pathogens in a body fluid
US5807881A (en) * 1992-05-27 1998-09-15 Quadra Logic Technologies, Inc. Method for selectively reducing activated leukocyte cell population
US5556992A (en) * 1994-09-02 1996-09-17 Universite De Montreal Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
CN1121217C (zh) * 1996-03-29 2003-09-17 特拉科斯有限公司 免疫原性组合物
US6350772B1 (en) * 1996-11-06 2002-02-26 Meiji Seika Kaisha, Ltd. Treatment of auto-immune diseases by photochemotherapy
AU748074B2 (en) * 1997-07-21 2002-05-30 Cerus Corporation Method of treating leukocytes, leukocyte compositions and methods of use thereof
WO1999007364A1 (fr) * 1997-08-05 1999-02-18 Meiji Seika Kaisha Ltd. Immunodepression par photochimiotherapie
AU753975B2 (en) * 1997-12-04 2002-10-31 Duke University Methods of isolating and using CD7+CD34-Lin-hematopoietic cells

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEASSEUR, N ET AL (2000), PHOTO CHEM. VOL 72(16):780-87 *
GUIMOND,M ET AL (2000) FASET J. VOL 14(6):A1074 *
HESHMATI,F ET AL(1997) THERAP. APHENESIS,VOL 1(2):121-125 *

Also Published As

Publication number Publication date
CA2382885C (en) 2010-06-29
KR20020050234A (ko) 2002-06-26
KR100697400B1 (ko) 2007-03-20
WO2001024824A1 (en) 2001-04-12
ES2234668T3 (es) 2005-07-01
DE60017201T2 (de) 2005-12-29
EP1267931B1 (de) 2004-12-29
JP2011229537A (ja) 2011-11-17
JP5476342B2 (ja) 2014-04-23
BR0014135A (pt) 2002-05-21
MXPA02003522A (es) 2004-09-10
AU7635700A (en) 2001-05-10
DE60017201D1 (de) 2005-02-03
JP4859319B2 (ja) 2012-01-25
JP2003510372A (ja) 2003-03-18
PT1267931E (pt) 2005-05-31
JP2011093939A (ja) 2011-05-12
ATE285793T1 (de) 2005-01-15
CA2699662A1 (en) 2001-04-12
CA2382885A1 (en) 2001-04-12
EP1267931A1 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
JP5476342B2 (ja) 光力学診断及び治療のためのローダミン誘導体
US8802082B2 (en) Rhodamine derivatives for photodynamic diagnosis and treatment
US5556992A (en) Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias
US20090104212A1 (en) Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
EP3134082B1 (de) Modifikation der extrakorporalen photopherese technologie mit porphyrin-vorläufern
US8383672B2 (en) Halogenated rhodamine derivatives and applications thereof
Brasseur et al. Eradication of Multiple Myeloma and Breast Cancer Cells by TH9402‐mediated Photodynamic Therapy: Implication for Clinical Ex Vivo Purging of Autologous Stem Cell Transplants¶
Holien et al. Comparison between 8‐methoxypsoralen and 5‐aminolevulinic acid in killing T cells of photopheresis patients ex vivo
Daziano et al. Preferential photoinactivation of leukemia cells by aluminum phthalocyanine
JP2004518766A (ja) ハロゲン化ローダミン誘導体およびその適用
SK93797A3 (en) Method to prevent transplant rejection
US6159733A (en) Method for photoinactivating malignant cells
Keij et al. Evaluation of the silicon phthalocyanine Pc 4 for photodynamic bone marrow purging
Dai TH9402 mediated photodynamic therapy: implications for ex vivo purging and tumor vaccination

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTORS TO INCLUDE: LUC VILLENEUVE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20030220

MK14 Patent ceased section 143(a) (annual fees not paid) or expired